Get the Stockscreener App
6.87
0.43%
-0.03
Pre-market:
6.88
0.010
+0.15%
Organon Co stock is traded at $6.87, with a volume of 3.15M.
It is down -0.43% in the last 24 hours and down -17.13% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.90
Open:
$6.96
24h Volume:
3.15M
Relative Volume:
0.61
Market Cap:
$1.79B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.5518
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-8.52%
1M Performance:
-17.13%
6M Performance:
-29.03%
1Y Performance:
-51.92%
1-Day Range:
$6.83
$7.06
1-Week Range:
$6.83
$7.495
52-Week Range:
$6.18
$16.08
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.87 | 1.80B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,003.57 | 899.90B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.30 | 594.64B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
236.19 | 413.50B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
165.15 | 313.28B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.53 | 312.88B | 58.80B | 10.24B | 8.98B | 3.2788 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²
Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com
Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI
Organon enters into agreement to license Miudella® - marketscreener.com
First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan
Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st
Organon rises after update on independent review - MSN
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat
Sector Update: Health Care - marketscreener.com
Organon Says Audit Review of Biosimilar Purchases Finds No Issues - marketscreener.com
Organon & Co. audit committee completes review of biosimilar purchase timing By Investing.com - Investing.com South Africa
Organon & Co. audit committee completes review of biosimilar purchase timing - Investing.com Nigeria
Organon rises after update on independent review (OGN:NYSE) - Seeking Alpha
Organon Audit Review Finds No Issues, 10-K On Track - TipRanks
Organon shares jump 6% after audit finds no misconduct By Investing.com - Investing.com India
Organon shares jump 6% after audit finds no misconduct - Investing.com
Organon (OGN) audit review finds no misconduct, plans timely 2025 10-K - Stock Titan
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):